Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.

de Bruyn M, Ringold R, Martens E, Ferrante M, Van Assche G, Opdenakker G, Dukler A, Vermeire S.

J Crohns Colitis. 2019 Oct 19. pii: jjz125. doi: 10.1093/ecco-jcc/jjz125. [Epub ahead of print]

PMID:
31628842
2.

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.

Lie MRKL, Kreijne JE, Dijkstra G, Löwenberg M, van Assche G, West RL, van Noord D, van der Meulen-de Jong AE, Oldenburg B, Zaal RJ, Hansen BE, de Vries AC, van der Woude CJ; Dutch Initiative on Crohn and Colitis (ICC).

Clin Gastroenterol Hepatol. 2019 Oct 11. pii: S1542-3565(19)31100-0. doi: 10.1016/j.cgh.2019.09.049. [Epub ahead of print]

PMID:
31610337
3.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group.

N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.

PMID:
31553833
4.

Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.

Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M.

J Crohns Colitis. 2019 Aug 29. pii: jjz151. doi: 10.1093/ecco-jcc/jjz151. [Epub ahead of print]

PMID:
31504343
5.

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases.

Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, Ferrante M.

Clin Gastroenterol Hepatol. 2019 Aug 22. pii: S1542-3565(19)30905-X. doi: 10.1016/j.cgh.2019.08.030. [Epub ahead of print]

6.

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M.

Inflamm Bowel Dis. 2019 Aug 10. pii: izz167. doi: 10.1093/ibd/izz167. [Epub ahead of print]

PMID:
31400283
7.

Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13.

Creyns B, Cremer J, Hoshino T, Geboes K, de Hertogh G, Ferrante M, Vermeire S, Ceuppens JL, Van Assche G, Breynaert C.

Sci Rep. 2019 Jul 11;9(1):10064. doi: 10.1038/s41598-019-46472-6.

8.

Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease.

Bislenghi G, Wolthuis A, Van Assche G, Vermeire S, Ferrante M, D'Hoore A.

Expert Opin Biol Ther. 2019 Jul;19(7):607-616. doi: 10.1080/14712598.2019.1623876. Epub 2019 Jun 3.

PMID:
31121104
9.

Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease.

Coenen S, Weyts E, Geens P, Vermeire S, Ferrante M, Vanhaecht K, Van Assche G.

Scand J Gastroenterol. 2019 May;54(5):592-596. doi: 10.1080/00365521.2019.1616214. Epub 2019 May 18.

PMID:
31106617
10.

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades.

Moens A, Verstockt B, Machiels K, Bossuyt P, Verdonck A, Lagrou K, van Assche G, Vermeire S, Ferrante M.

Eur J Gastroenterol Hepatol. 2019 Jun;31(6):668-673. doi: 10.1097/MEG.0000000000001394.

PMID:
30839436
11.

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.

Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A.

J Crohns Colitis. 2019 Sep 27;13(10):1248-1256. doi: 10.1093/ecco-jcc/jjz050.

PMID:
30820530
12.

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.

Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, Ferrante M.

J Crohns Colitis. 2019 Jul 25;13(7):864-872. doi: 10.1093/ecco-jcc/jjz008.

PMID:
30715258
13.

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.

Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, Breynaert C, Van Assche G, Vermeire S, Ferrante M.

EBioMedicine. 2019 Feb;40:733-742. doi: 10.1016/j.ebiom.2019.01.027. Epub 2019 Jan 24.

14.

Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.

Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, Ferrante M, Breynaert C.

Aliment Pharmacol Ther. 2019 Mar;49(5):572-581. doi: 10.1111/apt.15126. Epub 2019 Jan 20.

PMID:
30663072
15.

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, Van Lommel L, Schuit F, Van Assche G, Rutgeerts P, Ferrante M, Vermeire S, Arijs I, Cleynen I.

J Crohns Colitis. 2019 Jul 25;13(7):916-930. doi: 10.1093/ecco-jcc/jjz007.

PMID:
30657881
16.

Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial.

Roelandt P, Demedts I, Willekens H, Bessissow T, Braeye L, Coremans G, Cuyle PJ, Ferrante M, Gevers AM, Hiele M, Osselaer M, Tack J, Tejpar S, Ulenaers M, Van Assche G, Van Cutsem E, Van Gool S, Vannoote J, Vermeire S, Bisschops R.

Endoscopy. 2019 Mar;51(3):237-243. doi: 10.1055/a-0755-7471. Epub 2019 Jan 15.

PMID:
30646403
17.

Optimising infliximab induction dosing for patients with ulcerative colitis.

Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T.

Br J Clin Pharmacol. 2019 Apr;85(4):782-795. doi: 10.1111/bcp.13859. Epub 2019 Feb 10.

PMID:
30634202
18.

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.

J Pediatr Gastroenterol Nutr. 2019 Jun;68(6):847-853. doi: 10.1097/MPG.0000000000002265.

PMID:
30633108
19.

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.

Ther Drug Monit. 2019 Jun;41(3):317-324. doi: 10.1097/FTD.0000000000000601.

PMID:
30633088
20.

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease.

Verstockt B, Perrier C, De Hertogh G, Cremer J, Creyns B, Van Assche G, Ferrante M, Ceuppens JL, Vermeire S, Breynaert C.

Front Immunol. 2018 Dec 18;9:2983. doi: 10.3389/fimmu.2018.02983. eCollection 2018.

21.

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384.

22.

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A.

AAPS J. 2018 Dec 18;21(1):10. doi: 10.1208/s12248-018-0282-x.

PMID:
30564993
23.

Vedolizumab in Refractory Microscopic Colitis: An International Case Series.

Rivière P, Münch A, Michetti P, Chande N, de Hertogh G, Schoeters P, Ferrante M, Vermeire S, Van Assche G.

J Crohns Colitis. 2019 Mar 26;13(3):337-340. doi: 10.1093/ecco-jcc/jjy169.

PMID:
30329034
24.

No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts' Scoring System.

Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D'Hoore A, Laharie D, Ferrante M.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1643-1645. doi: 10.1016/j.cgh.2018.09.047. Epub 2018 Oct 4.

PMID:
30291910
25.

When IBD is not IBD.

Verstockt B, Vermeire S, Van Assche G, Ferrante M.

Scand J Gastroenterol. 2018 Sep;53(9):1085-1088. doi: 10.1080/00365521.2018.1500637. Epub 2018 Sep 26.

PMID:
30256685
26.

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.

J Crohns Colitis. 2018 Nov 15;12(11):1316-1325. doi: 10.1093/ecco-jcc/jjy111.

PMID:
30239644
27.

Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.

Ben-Horin S, Van Assche G, Chowers Y, Fudim E, Ungar B, Picard O, Yavzori M, Kopylov U, Mao R, Chen MH, Peled Y, Gueta I, Eliakim R, Loebstein R, Markovits N.

J Crohns Colitis. 2018 Nov 28;12(12):1410-1417. doi: 10.1093/ecco-jcc/jjy122.

PMID:
30169593
28.

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.

Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M.

Aliment Pharmacol Ther. 2018 Oct;48(7):731-739. doi: 10.1111/apt.14943. Epub 2018 Aug 15.

PMID:
30109889
29.

Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study.

Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, Ferrante M.

United European Gastroenterol J. 2018 Jun;6(5):765-772. doi: 10.1177/2050640617752207. Epub 2018 Jan 8.

30.

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, Ferrante M.

Gut. 2019 Aug;68(8):1531-1533. doi: 10.1136/gutjnl-2018-316845. Epub 2018 Jul 14. No abstract available.

PMID:
30007919
31.

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.

Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2018 Aug;48(3):347-357. doi: 10.1111/apt.14853. Epub 2018 Jun 19.

32.

Endoscopic management of Crohn's strictures.

Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G.

World J Gastroenterol. 2018 May 7;24(17):1859-1867. doi: 10.3748/wjg.v24.i17.1859. Review.

33.

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25.

PMID:
29704680
34.

New treatment options for inflammatory bowel diseases.

Verstockt B, Ferrante M, Vermeire S, Van Assche G.

J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. Review.

35.

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.

Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S.

Eur J Gastroenterol Hepatol. 2018 May;30(5):539-545. doi: 10.1097/MEG.0000000000001091.

PMID:
29462028
36.

Balloon Dilation of Intrinsic Small Bowel Strictures: Still Doubts About Its Efficacy?

Bessissow T, Van Assche G.

J Crohns Colitis. 2018 Mar 28;12(4):387-388. doi: 10.1093/ecco-jcc/jjy009. No abstract available.

PMID:
29377986
37.

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators.

Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.

PMID:
29277560
38.

Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology.

Noben M, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, Ferrante M.

United European Gastroenterol J. 2017 Dec;5(8):1073-1081. doi: 10.1177/2050640617722903. Epub 2017 Jul 21. Review.

39.

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A.

Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11.

40.

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1276-1283.e1. doi: 10.1016/j.cgh.2017.11.046. Epub 2017 Dec 1.

PMID:
29203225
41.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H.

Aliment Pharmacol Ther. 2018 Jan;47(2):219-228. doi: 10.1111/apt.14420. Epub 2017 Nov 21.

42.

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A.

Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255.

PMID:
29140943
43.

Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice.

Germain A, de Buck van Overstraeten A, Wolthuis A, Ferrante M, Vermeire S, Van Assche G, D'Hoore A.

Colorectal Dis. 2018 Feb;20(2):O30-O38. doi: 10.1111/codi.13948.

PMID:
29091335
44.

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease.

Vanhove W, Nys K, Arijs I, Cleynen I, Noben M, De Schepper S, Van Assche G, Ferrante M, Vermeire S.

J Crohns Colitis. 2018 Jan 24;12(2):178-187. doi: 10.1093/ecco-jcc/jjx122.

45.

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.

Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D'Hoore A.

J Crohns Colitis. 2017 Oct 27;11(11):1353-1361. doi: 10.1093/ecco-jcc/jjx095.

PMID:
28981886
46.

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.

Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S.

J Crohns Colitis. 2018 Jan 5;12(1):32-38. doi: 10.1093/ecco-jcc/jjx110.

PMID:
28981768
47.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

48.

Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres.

de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A.

Br J Surg. 2017 Nov;104(12):1713-1722. doi: 10.1002/bjs.10595. Epub 2017 Jul 26.

PMID:
28745410
49.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2018 Jun;67(6):1087-1094. doi: 10.1136/gutjnl-2016-313213. Epub 2017 Jul 11.

PMID:
28698230
50.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.

Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16.

PMID:
28622097

Supplemental Content

Loading ...
Support Center